Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic β-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications
Source abstract
Abstract
INTRODUCTION: Current trials for β-cell transplantation have been hindered by poor cell viability and function post-transplantation. Recently, electric charges of the microencapsulating formulation carrying β-cells have shown significant effects on cell survival and function. Thus, this study aimed at investigating the effects of electric charge, of novel colloidal formulation containing β-cells, on cell viability, biological activity and insulin release. METHODS: A new formulation, containing high ratios of poly-L-ornithine, suspending electrical-stimulation hydrogel and polystyrene sulphone (1:1:0.1 ratio), was used to form microcapsules utilizing 800 V and 2000 Hz encapsulating conditions. The bile acid, ursodeoxycholic acid, was added into the microcapsules to measure its effects on electric charges. RESULTS: The electric charge of the microencapsulating formulation was enhanced by bile acid addition, and resulted in better cell viability and function. CONCLUSION: Ursodeoxycholic acid microencapsulated with poly-L-ornithine, suspending electrical-stimulation hydrogel and polystyrene sulphone at 1:1:0.1 ratio, using 800 V and 2000 Hz microencapsulating conditions, produced enhanced electrokinetic parameters of microcapsules with optimized cell functions. This suggests that electric charge of formulations containing pancreatic β-cell may have significant effects on cell mass and functions, post-transplantation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Polymer Surface Interaction Studies · Erythrocyte Function and Pathophysiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia;
School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia;
Centre for Medical Research, University of Western Australia, Perth, WA, Australia;
Clinical Sciences Division, The Harry Perkins Institute of Medical Research, Perth, WA, Australia
References (42)
Show source-provided references
1. 10.1007/s12668-016-0198-910.1007/s12668-016-0198-9 ↗
2. 10.1007/s12195-016-0441-z10.1007/s12195-016-0441-z ↗
3. Negrulj R · J Endocrinol Diabet Mellit · 2013 · 1 · 49
4. 10.1007/s13346-015-0248-910.1007/s13346-015-0248-9 ↗
5. 10.1097/TP.000000000000028610.1097/TP.0000000000000286 ↗
6. 10.1007/s13346-015-0268-510.1007/s13346-015-0268-5 ↗
7. 10.4155/tde-2015-000110.4155/tde-2015-0001 ↗
8. 10.1007/s11095-016-1863-y10.1007/s11095-016-1863-y ↗
9. 10.3109/21691401.2014.93445710.3109/21691401.2014.934457 ↗
10. 10.3109/21691401.2014.97180610.3109/21691401.2014.971806 ↗
11. 10.3109/10837450.2014.91557010.3109/10837450.2014.915570 ↗
12. 10.1007/s12247-016-9248-710.1007/s12247-016-9248-7 ↗
13. 10.2174/157339981266615122910175610.2174/1573399812666151229101756 ↗
14. 10.1080/02652048.2016.122870310.1080/02652048.2016.1228703 ↗
15. 10.1504/IJNBM.2016.07968410.1504/IJNBM.2016.079684 ↗
16. 10.1002/btpr.222310.1002/btpr.2223 ↗
17. 10.3109/21691401.2014.93445710.3109/21691401.2014.934457 ↗
18. 10.3109/21691401.2015.106929910.3109/21691401.2015.1069299 ↗
19. 10.1002/btpr.222310.1002/btpr.2223 ↗
20. 10.1002/jbm.a.3097910.1002/jbm.a.30979 ↗
21. 10.1016/j.addr.2013.07.01010.1016/j.addr.2013.07.010 ↗
22. 10.2174/157339981266615122910175610.2174/1573399812666151229101756 ↗
23. 10.1021/acs.molpharmaceut10.1021/acs.molpharmaceut ↗
24. 10.1080/10837450.2017.132166410.1080/10837450.2017.1321664 ↗
25. 10.1007/s11095-017-2138-y10.1007/s11095-017-2138-y ↗
26. 10.1111/j.1440-1711.2005.01397.x10.1111/j.1440-1711.2005.01397.x ↗
27. 10.2337/diab.40.7.84210.2337/diab.40.7.842 ↗
28. Negrulj R · Artif Cells Nanomed Biotechnol · 2015 · 44 · 129010.3109/21691401.2015.1024845 ↗
29. Mooranian A · Drug Design Develop Ther · 2014 · 8 · 1003
30. Mooranian A · Drug Des Develop Ther · 2014 · 8 · 1221
31. Mooranian A · Drug Des Devel Ther · 2014 · 8 · 1673
32. 10.1007/s12247-014-9182-510.1007/s12247-014-9182-5 ↗
33. 10.3109/02652048.2014.95820410.3109/02652048.2014.958204 ↗
34. 10.1208/s12249-014-0205-910.1208/s12249-014-0205-9 ↗
35. 10.3109/02652048.2015.106592210.3109/02652048.2015.1065922 ↗
36. 10.3109/10837450.2010.50289810.3109/10837450.2010.502898 ↗
37. 10.1007/s00125005067310.1007/s001250050673 ↗
38. 10.1007/s00125-001-0729-x10.1007/s00125-001-0729-x ↗
39. Kullmann F · Z Gastroenterol · 1997 · 35 · 171
40. 10.1016/j.intimp.2012.11.01710.1016/j.intimp.2012.11.017 ↗
41. 10.1016/j.addr.2013.11.00510.1016/j.addr.2013.11.005 ↗
42. 10.1016/j.cocis.2005.05.00410.1016/j.cocis.2005.05.004 ↗